Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/23/11
End: 05/26/15
Due: 05/26/16
Phase: N/A
Priority: Normal
Start: 07/14/15
End: 05/18/18
Due: 05/18/19
Phase: N/A
Priority: Normal
Start: 01/22/07
End: 01/20/10
Due: 01/20/11
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | NCT01383538 | Andrew Ko | user2@example.com | None | 2011-08-23 | 2015-05-26 | 2016-05-26 | - | - | 2025-07-14 |
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | NCT02487277 | Andrew Ko | user2@example.com | None | 2015-07-14 | 2018-05-18 | 2019-05-18 | - | - | 2025-07-14 |
| Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | NCT00429858 | Andrew Ko | user2@example.com | None | 2007-01-22 | 2010-01-20 | 2011-01-20 | - | - | 2025-07-14 |